VYYRF (Voyageur Pharmaceuticals) Moat Score: 2/10 (As of Jul. 01, 2026)


VYYRF Voyageur Pharmaceuticals Ltd VYYRF
18 GF Score
Price $0.10
! 5 Warning Signs
View Full Analysis

What is Voyageur Pharmaceuticals Moat Score?

Voyageur Pharmaceuticals VYYRF 18 Moat Score is 2 as of Jul. 01, 2026. GuruFocus rates VYYRF with a GF Score™ of 18/100. The stock has 5 warning signs investors should review. Among 1,031 Drug Manufacturers companies, Voyageur Pharmaceuticals ranks better than 81.67% on this metric.

Voyageur Pharmaceuticals has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Voyageur Pharmaceuticals has No Moat: Voyageur Pharmaceuticals has some intellectual property but lacks significant market share, brand strength, or regulatory barriers, resulting in a very weak moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Voyageur Pharmaceuticals might have No Moat - Very weak/transient advantages.

Voyageur Pharmaceuticals  (OTCPK:VYYRF) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Voyageur Pharmaceuticals Moat Score Related Terms

VYYRF vs ZTS, UTHR: Moat Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Voyageur Pharmaceuticals's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Voyageur Pharmaceuticals Moat Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Voyageur Pharmaceuticals's Moat Score distribution charts can be found below:

* The bar in red indicates where Voyageur Pharmaceuticals's Moat Score falls into.


VYYRF
18GF Score
Voyageur Pharmaceuticals Ltd VYYRF
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Voyageur Pharmaceuticals (VYYRF) has a Moat Score of 2 as of Jul. 01, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Voyageur Pharmaceuticals ranks #189 out of 1031 companies in the Drug Manufacturers industry, placing it in the top 18.3%.
Is Voyageur Pharmaceuticals' Moat Score too high?
Voyageur Pharmaceuticals' current Moat Score is 2. Based on the distribution chart, Voyageur Pharmaceuticals ranks #189 out of 1031 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Voyageur Pharmaceuticals has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Voyageur Pharmaceuticals' Moat Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Voyageur Pharmaceuticals ranks #189 out of 1031 companies for Moat Score. This places Voyageur Pharmaceuticals in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Drug Manufacturers company?
A good Moat Score depends on the Drug Manufacturers industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. Voyageur Pharmaceuticals's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Voyageur Pharmaceuticals stock overvalued right now?
Voyageur Pharmaceuticals (VYYRF) has a current Moat Score of 2. The current Moat Score is 2. Voyageur Pharmaceuticals' overall GF Score™ is 18/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Voyageur Pharmaceuticals (VYYRF), the current Moat Score is 2 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Voyageur Pharmaceuticals Business Description

Other Exchanges VM:Canada
Address 4103B Center Street NW, Calgary, AB, CAN, T2E 2Y6
Voyageur Pharmaceuticals Ltd is a Canadian development-stage pharmaceutical company developing and selling barium and iodine active pharmaceutical ingredients (API) and high-performance, cost-effective imaging contrast agents for medical radiology. Its product portfolio comprises SmoothX (a barium sulfate suspension), SmoothHD, SmoothLD (a low-density barium suspension solution), VisionHD (a high-density barium powder suspension), VisionLD, V-Gas, and others. Additionally, the company has interests in two mineral properties: Frances Creek and Jubilee Mountain, located in the province of British Columbia, Canada, and the ULI Project in the state of Utah, United States of America.
18GF Score

Get the complete analysis for VYYRF

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.10
Price